Patents by Inventor MIKE NEDELCOVYCH

MIKE NEDELCOVYCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS
    Publication number: 20240041900
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Application
    Filed: October 2, 2023
    Publication date: February 8, 2024
    Inventors: Barbara Slusher, David Volsky, Mike Nedelcovych, Kristen Hollinger, Atsushi Kamiya
  • GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS
    Publication number: 20220241299
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Application
    Filed: September 3, 2021
    Publication date: August 4, 2022
    Inventors: BARBARA SLUSHER, DAVID VOLSKY, MIKE NEDELCOVYCH, KRISTEN HOLLINGER, ATSUSHI KAMIYA
  • Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
    Patent number: 11110104
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 7, 2021
    Assignees: The Johns Hopkins University, Icahn School of Medicine at Mount Sinai
    Inventors: Barbara Slusher, David Volsky, Mike Nedelcovych, Kristen Hollinger, Atsushi Kamiya
  • GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS
    Publication number: 20180193362
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Application
    Filed: January 31, 2018
    Publication date: July 12, 2018
    Inventors: BARBARA SLUSHER, DAVID VOLSKY, MIKE NEDELCOVYCH, KRISTEN HOLLINGER, ATSUSHI KAMIYA